TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study Comparing the Safty Anf Efficacy of Ranibizumab (Lucentis®) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO
Brief Summary: A prospective multicenter study comparing patients with CRVO amd secondary macular edema treated with ranibizumab versus sham. Safety and efficacy will be evaluated. Patients will be randomized in a 1:1 ratio to one of the two arms. 32 patients, 6 months follow up. There will be monthly visits with injection the first three months and subsequently new injection if present edema.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): B
B: Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: Ranibizumab injection 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.3 mg | Arm Label: Ranibizumab injection 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection | Intervention Type: DRUG; Name: Ranibizumab injection 0.3 mg; Assigned to Arm(s): Ranibizumab injection 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.5 mg; Assigned to Arm(s): Ranibizumab injection 0.5 mg
C: Arm Label: CRVO Observation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: CRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: CRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: BRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): BRVO standard care, CRVO Observation | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 1 mg dose triamcinolone acetonide, CRVO 1 mg dose triamcinolone acetonide | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 4 mg dose triamcinolone acetonide, CRVO 4 mg dose triamcinolone acetonide
D: Intervention Type: DRUG; Name: Intravitreal Triamcinolone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Radial Optic Neurotomy; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Placebo - Sham Intravitreal Injection; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone
Brief Summary: This is a prospective, six-week, randomized, double blind, placebo-controlled, multi-center study in patients with schizophrenia who are experiencing an acute exacerbation of psychosis.


Options:
A: Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol
B: Arm Label: RISPERDAL CONSTA; Type: ACTIVE_COMPARATOR; Interventions: Drug: RISPERDAL CONSTA | Arm Label: R092670; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone palmitate | Intervention Type: DRUG; Name: RISPERDAL CONSTA; Assigned to Arm(s): RISPERDAL CONSTA | Intervention Type: DRUG; Name: Paliperidone palmitate; Assigned to Arm(s): R092670
C: Arm Label: Risperidone LAI; Type: OTHER; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone LAI
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: BL - 1020 | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: BL - 1020 | Arm Label: III; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: BL - 1020; Assigned to Arm(s): I | Intervention Type: DRUG; Name: BL - 1020; Assigned to Arm(s): II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): IV

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control
Brief Summary: This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.


Options:
A: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100mcg/Vilanterol 25mcg | Arm Label: Fluticasone Propionate/Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticaosne Propionate 500mcg/Salmeterol 50mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100mcg/Vilanterol 25mcg; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticaosne Propionate 500mcg/Salmeterol 50mcg; Assigned to Arm(s): Fluticasone Propionate/Salmeterol
B: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 62.5/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 62.5mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 62.5/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 62.5mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to Salmeterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Salmeterol | Arm Label: Salmeterol 50 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 μg, Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Salmeterol 50 μg; Assigned to Arm(s): Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Placebo, Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Salmeterol; Assigned to Arm(s): Indacaterol 150 μg, Placebo
D: Arm Label: NVA237 100 µg; Type: EXPERIMENTAL; Interventions: Drug: NVA237 100 µg | Arm Label: NVA237 200 µg; Type: EXPERIMENTAL; Interventions: Drug: NVA237 200 µg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NVA237 100 µg; Assigned to Arm(s): NVA237 100 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: NVA237 200 µg; Assigned to Arm(s): NVA237 200 µg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control
Brief Summary: This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.


Options:
A: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
B: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to Salmeterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Salmeterol | Arm Label: Salmeterol 50 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 μg, Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Salmeterol 50 μg; Assigned to Arm(s): Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Placebo, Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Salmeterol; Assigned to Arm(s): Indacaterol 150 μg, Placebo
C: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
D: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control
Brief Summary: This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.


Options:
A: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
B: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to Salmeterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Salmeterol | Arm Label: Salmeterol 50 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 μg, Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Salmeterol 50 μg; Assigned to Arm(s): Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Placebo, Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Salmeterol; Assigned to Arm(s): Indacaterol 150 μg, Placebo
C: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
D: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control
Brief Summary: This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.


Options:
A: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol | Arm Label: Indacaterol 300 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 150 µg, Indacaterol 300 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg capsules | Arm Label: Indacaterol 300 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Indacaterol 150 μg capsules; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Indacaterol 300 μg capsules; Assigned to Arm(s): Indacaterol 300 µg | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
C: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to Salmeterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Salmeterol | Arm Label: Salmeterol 50 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 μg, Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Salmeterol 50 μg; Assigned to Arm(s): Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Placebo, Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Salmeterol; Assigned to Arm(s): Indacaterol 150 μg, Placebo
D: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg | Arm Label: Indacaterol 300 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg | Arm Label: Placebo to indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Indacaterol 300 μg; Assigned to Arm(s): Indacaterol 300 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Placebo to indacaterol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antipyretics for Preventing Recurrences of Febrile Seizures
Brief Summary: We wanted to find out if the early use of antipyretics is capable in preventing recurrences of febrile seizures. When a child has had his/her first febrile seizure, the parents were instructed to give him/her antipyretic medication every time when the child had a new episode of fever during two years.


Options:
A: Arm Label: 1 drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 2 drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 3 drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 4 drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 5 drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Intervention Type: DRUG; Name: Diclofenac, Paracetamol, Ibuprofen; Assigned to Arm(s): 1 drug, 2 drug, 3 drug, 4 drug, 5 drug
B: Arm Label: Intranasal Midazolam 0.2mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Rectal Diazepam 0.3-0.5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diazepam | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Intranasal Midazolam 0.2mg/kg | Intervention Type: DRUG; Name: Diazepam; Assigned to Arm(s): Rectal Diazepam 0.3-0.5 mg/kg
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Lorazepam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: intranasal lorazepam; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: intramuscular paraldehyde; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Simplified Detection of Dynamic Hyperinflation Using Metronome Paced Hyperventilation and the Effect of Tiotropium in Patients With COPD
Brief Summary: We will detect dynamic hyperinflation (DH) in 40 COPD (chronic obstructive pulmonary disease) patients with moderately severe disease using metronome paced hyperventilation (MPH) with inspiratory capacity as the primary end point. Hypothesis: Is tiotropium capable of lung volume protecting inspiratory capacity from MPH induced DH vs placebo in a randomized crossover double blinded study.


Options:
A: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Tiotropium 18 µg capsule, bronchodilator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2, Tiotropium 18 µg capsule, bronchodilator
D: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Rehabilitation for Patients Living With an ICD
Brief Summary: The purpose of this study is to describe the effect and meaning of an outpatient-nursing programme including physical activity for patients with implantable cardioverter defibrillators (ICD).

Hypothesis: The outpatient nursing programme will increase the perceived health and quality of life; improve the management of life from a patient perspective; reduce fear of exercise and increase physical capability and reduce the number of treatment-demanding arrhythmias.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2
B: Arm Label: Cognitive Behavior Therapy - males; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Cognitive Behavior Therapy - females; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Usual Cardiac Care - Males; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Arm Label: Usual Cardiac Care - females; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Intervention Type: BEHAVIORAL; Name: Cognitive Behaviour Therapy (CBT); Assigned to Arm(s): Cognitive Behavior Therapy - females, Cognitive Behavior Therapy - males | Intervention Type: OTHER; Name: Usual Cardiac Care (UCC); Assigned to Arm(s): Usual Cardiac Care - Males, Usual Cardiac Care - females
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: rehabilitation; Assigned to Arm(s): 1
D: Arm Label: Aerobic Exercise Program; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Program | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Program; Assigned to Arm(s): Aerobic Exercise Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Rehabilitation for Patients Living With an ICD
Brief Summary: The purpose of this study is to describe the effect and meaning of an outpatient-nursing programme including physical activity for patients with implantable cardioverter defibrillators (ICD).

Hypothesis: The outpatient nursing programme will increase the perceived health and quality of life; improve the management of life from a patient perspective; reduce fear of exercise and increase physical capability and reduce the number of treatment-demanding arrhythmias.


Options:
A: Arm Label: Regular treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): Psychoeducation
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary intervention | Arm Label: Controll group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group, Brief Intervention | Intervention Type: BEHAVIORAL; Name: Interdisciplinary intervention; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Control Group, Brief Intervention; Assigned to Arm(s): Controll group
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: rehabilitation; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Care manager outreach and monitoring; Assigned to Arm(s): N/A

Answer: C